Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label AFQ056 (mavoglurant) treatment in Parkinson's disease patients with L-dopa-induced dyskinesia
2011-004378-27Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavoglurant in levodopa-induced dyskinesia (LID) and Parkinson's disease (PD), sponsored by Novartis. Primary endpoint: Incidence rate of adverse events including serious adverse events. Started Feb 2012; status: terminated.
02
Drugs
mavoglurant
03
Conditions
levodopa-induced dyskinesia (LID)Parkinson's disease (PD)
Beyond the preview
Go deeper on 2011-004378-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004378-27.